Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts
–Gaye Bok appointed Senior Director, Commercial Development;
Microbia’s initial focus is on developing specialty chemicals based on a proprietary biomanufacturing platform. The company’s pipeline includes two carotenoid products for use in human and animal nutrition markets that are traditionally manufactured from petrochemical-derived raw materials. Currently at the commercialization stage, Microbia believes its natural fermentation-based processes for these products offer significant cost advantages over traditional chemical synthesis methods, with the additional advantage of being based on renewable raw materials.
“The recruitment of
ABOUT MICROBIA PE (www.microbia-pe.com)
Microbia is an industrial biotechnology company applying proprietary metabolic engineering approaches to create novel, commercially valuable specialty ingredients and biomaterials. Microbia’s products are generated from renewable raw materials and either replace existing petrochemical-derived counterparts in a cost-effective manner, or introduce new industrial chemicals with applications as novel biomaterials. Microbia is commercializing its technology through internal product development programs as well as strategic alliances, including an ongoing multiproduct joint development and commercialization agreement with Tate & Lyle Investments, Ltd. Microbia was established in 2006 as a majority-owned subsidiary of Ironwood Pharmaceuticals, Inc. and is based in
Contact: Mary Moynihan M2Friend Biocommunications 802.951.9600 email@example.com
SOURCE Microbia Precision Engineering, Inc.